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Preterm birth is a delivery that occurs at less than 37 completed weeks of gestation and it is associated with perinatal morbidity and
mortality. Spontaneous preterm birth accounts for up to 75% of all preterm births. A number of maternal or fetal characteristics
have been associated with preterm birth, but the use of individual or group biochemical markers have advanced some of the
understanding on the mechanisms leading to spontaneous preterm birth. This paper provides a summary on the current literature
on the use of biochemical markers in predicting spontaneous preterm birth in asymptomatic women. Evidence from the literature
suggests fetal fibronectin, cervical interleukin-6, and 𝛼-fetoprotein as promising biochemical markers in predicting spontaneous
preterm birth in asymptomatic women. The role of gene-gene and gene-environment interactions, as well as epigenetics, has the
potential to further elucidate and improve understanding of the underlying mechanisms or pathways of spontaneous preterm
birth. Refinement in study design and methodology is needed in future research for the development and validation of individual
or group biochemical marker(s) for use independently or in conjunction with other potential risk factors such as genetic variants
and environmental and behavioral factors in predicting spontaneous preterm birth across diverse populations.
1. Introduction
Preterm birth is defined as birth at less than 37 completed
weeks of gestation and it accounts for approximately 75% of
perinatal mortality and nearly half of the cases of long-term
neurologic morbidity [1]. The rate of preterm births in the
United States was 12.8% in 2006, a rate that had increased
by more than 20% between 1990 and 2006 [2]. The estimated
annual health care cost due to preterm birth had exceededUS
$26 billion in 2005 or $51,600 per infant [3]. Preterm birth is
a heterogeneous phenotype with many biological pathways
[3] and is classified into two broad categories, spontaneous
and indicated, based on the presence or absence of factors
that place the mother or the fetus at risk [4–6]. Spontaneous
preterm birth (sPTB) accounts for the majority of preterm
births in developed countries and it occurs as a result of spon-
taneous onset of labor (40% to 45%) or preterm premature
rupture of fetal membranes (25% to 30%) before 37 weeks
of gestation. Preterm births that are the result of conditions
that directly threaten the health of the mother or fetus are
categorized as indicated preterm births and account for the
remaining 25% to 30% of preterm deliveries [4–7].
The onset of preterm labor is thought to be brought on
by multiple mechanisms or pathways that may have been
initiated weeks to months before the actual presence of clini-
cal symptoms [3, 8]. Various maternal or fetal demographic,
behavioral, and clinical characteristics have been associated
with preterm birth including maternal race/ethnicity [9, 10],
younger maternal age [11, 12], maternal age over 35 years
[13], cigarette smoking [14, 15], low prepregnancy weight [15–
17], psychosocial stress [18], previous preterm birth [19], and
intrauterine infection [20, 21].
The identification of risk factors for predicting preterm
birth is advantageous because it allows for the initiation of
risk-specific treatment for at-risk women and these risk fac-
tors may provide insights into a better understanding of the
mechanisms leadingtopretermbirth[22, 23].However,meth-
ods for identifying women at risk of preterm birth by the
reliance of demographic, behavioral, and biological risk fac-
tors have low sensitivities [3]. Cervicovaginal fluids, amniotic
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fluid, urine, saliva, and serum or plasma are biologic fluids
that have been used as a source for identifying biochemical
markers for the prediction of preterm birth. For large-
scale, population-based clinical and epidemiological studies,
methodological and ethical considerations are critical as
researchers choose to incorporate the sampling of biological
specimens in otherwise asymptomatic women and such
considerations include cost, ease of specimen collection and
storage, and potential maternal and fetal risks. This paper
summarizes the current literature on biochemical markers of
sPTB in asymptomatic women, in which the focus is placed
solely on markers that offer a great degree of acceptability
to most pregnant women while minimizing maternal and
fetal risks. Thereby, biochemical markers that are collected
through invasive procedures such as amniocentesis are omit-
ted from this review.
2. Common Biological Pathways to
Preterm Birth
Biomarkers of sPTB are divided into mechanistic pathways
and they include intrauterine infection and inflammation,
extracellular matrix degradation, fetal stress, fetal anomalies,
and estrogen metabolism pathways (Table 1).
2.1. Intrauterine Infection and Inflammation Pathway
2.1.1. Bacterial Vaginosis. Bacterial vaginosis (BV) is an alter-
ation of the maternal vaginal flora in which normal lacto-
bacilli are replaced by Gram-negative anaerobic bacteria [24]
and diagnosed by Gram-stain Nugent score or by the Amsel
criteria. Positive results of BV are marker of intrauterine
infection in asymptomatic women [20] and the presence of
BVduring pregnancy is consistently associatedwith a twofold
increase in risk of spontaneous preterm birth [5, 25].
2.1.2. Inflammatory Response. Intrauterine infection is an
importantmechanism leading to pretermbirth [20]. Bacterial
invasion of the choriodecidual space activates the production
of a number of cytokines and these markers of inflammation
(interleukins [IL] 1, 2, 6, and 8, tumor necrosis factor-𝛼 [TNF-
𝛼], and C-reactive protein [CRP]) have been evaluated as
biomarkers in subsequent sPTB.
Interleukin-6. IL-6, a proinflammatory cytokine, is a major
mediator of host response to inflammation and infection.
It can be analyzed from samples of maternal cervical fluids
or serum and to date, IL-6 is one of the most well-studied
biomarkers of sPTB [26]. In a nested case-control study of
asymptomatic women matched for race, parity, and study
center [27], cervical IL-6 concentrations measured at 24
weeks of gestation were elevated in women who delivered at
<32 weeks of gestation (247 ± 365 versus 84 ± 129 pg/mL) and
at <35 weeks of gestation (212 ± 339 versus 111 ± 186 pg/mL)
compared to womenwho delivered at term. Furthermore, IL-
6 concentrations for women who delivered within 4 weeks
of specimen collection (384 ± 444 pg/mL) were statistically
significantly higher than those in their matched control (97
± 163 pg/mL). In a meta-analysis [28], an increased risk of
sPTB at <37 weeks of gestation in asymptomatic women was
associated with elevated levels of cervical IL-6 (OR = 3.1,
95% CI: 2.0, 4.7). Results from a study by Paternoster et al.
[29] further supported cervical IL-6 as a powerful indicator
for sPTB among asymptomatic pregnant women. Paternoster
and colleagues reported that concentrations of IL-6 at the
90th percentile or greater increased the risks for sPTB at <32
weeks’ gestation (OR = 4.3, 95% CI: 1.2, 14.7), at <35 weeks of
gestation (OR = 5.4, 95% CI: 1.8, 16.6), and at <37 weeks of
gestation (OR = 3.8, 95% CI: 1.2, 12.1).
Evidence in the literature to date has not shown serum
IL-6 to be a useful biomarker in predicting sPTB for asymp-
tomatic women. Paternoster et al. [29] and Kramer et al. [30]
found no association between maternal serum IL-6 around
24 weeks of gestation and sPTB, while Goldenberg et al. [31]
observed onlyweak effects onmaternal serumconcentrations
of IL-6 at 24 weeks of gestation on sPTB at <32 weeks’ (OR =
1.3) and at <35 weeks of gestation (OR = 1.1) in a nested case-
control study of asymptomatic women. A positive association
was seen between elevated serum IL-6 concentrations and
sPTB in a meta-analysis (OR = 1.5, 95% CI: 0.7, 3.0) [28];
however, this imprecise finding must be interpreted with
caution because only two studies contributed to the subgroup
analysis.
C-Reactive Protein. C-reactive protein (CRP) is a maternal
systemic inflammatory marker that has been evaluated in
the literature as a potential marker for preterm birth. In a
prospective nested case-control study, Hvilsom et al. [32]
examined maternal serum C-reactive protein (CRP) in early
second trimester (14–18 weeks) in relation to sPTB in asymp-
tomatic women. CRP concentrations ranged from 5.6 𝜇g/mL
(at 75th percentile) to 16.4 𝜇g/mL (at 95th percentile), and
elevated CRP concentrations in maternal serum (≥85th per-
centile) increased the risk of sPTB (OR = 2.0, 95% CI: 1.2, 3.5)
compared to lower CRP concentrations (<85th percentile). In
a subgroup analysis, womenwithout a previous preterm birth
but with CRP levels at the 90th percentile and the 95th
percentile had an increased risk of sPTB (OR = 2.1, 95% CI:
1.1, 4.3 and OR = 2.2, 95% CI: 0.9, 5.5, resp.) compared to
women with CRP levels at <75th percentile. Catov et al. [33]
reported an increased risk of early to moderate sPTB (<34
weeks of gestation; OR = 2.8, 95% CI: 1.1, 7.5) and late sPTB
(34weeks to<37weeks of gestation;OR= 2.6, 95%CI: 1.3, 5.5)
for the presence of early pregnancy serum CRP (≥8𝜇g/mL
obtained <21 weeks of gestation) in asymptomatic women.
Likewise, Riboni and colleagues [34] found an increase in
risk of sPTB (OR = 3.1, 95% CI: 1.4, 6.8) in elevated serum
CRP concentrations (≥8.4 𝜇g/mL) collected in mid-second
trimester. Other studies, in contrast, showed weak [28] to no
effects [30] of elevated serum CRP levels in predicting sPTB
among asymptomatic women; thereby, not corroborating
results from earlier research.
Other Inflammatory Cytokines, Tumor Necrosis Factor- 𝛼. In
addition to the evaluation of IL-6 and CRP in predicting
subsequent preterm birth, few earlier studies also evaluated
the association between other common cytokines IL-1, IL-2,
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IL-8, and TNF-𝛼 but there was no evidence suggesting that
elevated cytokine values were associated with an increased
risk of sPTB [29–31, 34].
2.2. Extracellular Matrix Degradation Pathway
2.2.1. Fetal Fibronectin. Thepresence of fetal fibronectin, thus
far, is the most effective biochemical marker for predicting
preterm birth [31, 35–39]. Fetal fibronectin, a stable glyco-
protein produced by the fetal membranes, adheres the fetal
membranes and placenta to the uterine lining [22, 40] and
plays a critical role in facilitating the physiological separation
of the placenta from the uterus after delivery [41]. Although
fetal fibronectin is generally not present at levels >50 ng/mL
between 16 and 22 weeks of gestation, earlier studies have
shown that its presence (>50 ng/mL) in the cervix or vagina
from22weeks of gestation and beyond is a powerful predictor
of subsequent sPTB [31, 35, 36, 38, 39, 42, 43]. Goldenberg
et al. [39] demonstrated that screening asymptomatic women
for the presence of cervical fetal fibronectin at 24 or 26 weeks
of gestation had a high sensitivity in predicting more than
60% of sPTB within the next 4 weeks (Sensitivity = 0.63, 95%
CI: 0.4, 0.8; relative risk = 59.2, 95% CI: 35.9, 97.8) compared
to women with a negative fetal fibronectin test (<50 ng/mL);
however, this association was weaker at 28 and 30 weeks of
gestation and for later gestational ages. In a related study [38],
29% of women were tested positive for cervical or vaginal
fetal fibronectin if the last fetal fibronectin test was positive
and 42% had a subsequent positive test result if two previous
tests were positive; however, only 3% of the next fibronectin
tests were positive if the previous fetal fibronectin test was
negative. Data from this study not only demonstrated the
presence of a positive fetal fibronectin test result predicted
subsequent positive test results, but also provided additional
evidence that the greater number of positive fetal fibronectin
results is associated with an increased risk of sPTB at <35
and <37 weeks of gestation. Morrison and colleagues [42]
also demonstrated the utility of cervical fetal fibronectin
as an assessment tool in predicting sPTB among high risk
asymptomatic women. Despite a small sample size, data
from this prospective cohort study showed that women with
positive fetal fibronectin (>50 ng/mL) had an increased risk
of sPTB prior to 34 weeks of gestation (relative risk = 3.8,
95% CI: 1.5, 9.4) compared to women with negative fetal
fibronectin; the risk of sPTB was further magnified when
positive fetal fibronectin was coupled with positive uterine
contraction (relative risk = 27.0, 95% CI: 8.7, 84.1). Similarly,
a positive cervical fetal fibronectin (>50 ng/mL) at 24 weeks’
gestation was found to be associated with sPTB at <32 weeks
of (odds ratio [OR] = 7.6, 95% CI: 3.0, 19.2) and at <35 weeks
of gestation (OR = 6.0, 95%CI: 2.4, 14.6) compared to women
with negative results [29]. In a cohort study of asymptomatic
pregnant women, Roman et al. [43] reported high negative
predictive values and specificities for vaginal fetal fibronectin
in predicting sPTB within 14 and 21 days of assessments and
for sPTB at <34 weeks of gestation.
The association between the presence of fetal fibronectin
and sPTB in asymptomatic women was further examined in
a meta-analysis by Honest et al. [44]. The likelihood ratio, an
indication of how much a given fetal fibronectin test result
increases or decreases the probability of having sPTB, was 4.0
(95% CI: 2.9, 5.5) for positive result of predicting birth before
34 weeks of gestation among asymptomatic women [44].
The fetal fibronectin test can be performed as a single test
or in series. A sample is collected from the posterior vaginal
fornix and cervix with a sterile swab and the sample is then
placed in a buffer solution and shipped to the laboratory for
assay. Ideally, this test should be used in clinical settings in
conjunction with patient medical history and other clinical
information to assess overall risk of sPTB.
2.3. Fetal Stress Pathway
2.3.1. Corticotropin-Releasing Hormone. Corticotropin-re-
leasing hormone (CRH) is expressed by the human placenta
and the fetal membranes, and its highest level of production
is seen during the third trimester [45]. In a retrospective
examination of plasma CRH levels from four gestational age
intervals, Berkowitz et al. [46] found no difference in the
overall mean CRH among asymptomatic women who deliv-
ered preterm and the mean CRH among women who deliv-
ered at term. Comparedwith termbirths, gestational age-spe-
cific CRH levels were not associated with predicting subse-
quent sPTB.
In contrast, analysis from a nested case-control study
of 254 asymptomatic women showed that elevated maternal
plasma CRH (>90th percentile) at 28 weeks of gestation was
associated with sPTB at <35 weeks (OR = 3.5, 95% CI: 1.0,
10.9) but high levels of CRH at 24 or 28 weeks of gestation
did not predict sPTB at <32 weeks of gestation or <37 weeks
of gestation [47]. A study by Goldenberg et al. [31] further
demonstrated similar trends in the association between CRH
levels and subsequent preterm birth.
2.4. Fetal Anomalies Pathway
2.4.1. 𝛼-Fetoprotein and 𝛽-Human Chorionic Gonadotropin.
Several earlier studies have identified elevated levels of 𝛽-
human chorionic gonadotropin (hCG) and 𝛼-fetoprotein to
be associatedwith an increased risk of sPTB in cervicovaginal
fluids among asymptomatic pregnant women [20, 22, 31, 48].
In a prospective cohort study of 540 asymptomatic women,
cervicovaginal hCG greater than 77.8mIU/mL had a sensitiv-
ity of 87.5% (95%CI: 47.4, 97.9), specificity of 97% (86.5, 99.4),
and adjusted OR = 20.0 (95% CI: 10.7, 37.5) in identifying
women with sPTB at ≤34 weeks of gestation [49]. Elevated
levels of 𝛼-fetoprotein were also associated with predicting
early and late preterm births. Moawad et al. [47] conducted a
nested case-control study with 127 asymptomatic women and
examined 𝛼-fetoprotein at 24 and 28 weeks of gestation and
subsequent sPTB. For 𝛼-fetoprotein measured at 24 weeks of
gestation, elevated values (>90th percentile) were found to
increase the risk of spontaneous preterm birth at <32 weeks
(OR= 8.3, 95%CI: 2.2, 30.9) and for sPTB at<35 weeks (OR=
3.5, 95% CI: 1.8, 6.7). The levels of 𝛼-fetoprotein measured at
28 weeks of gestation were also associated with subsequent
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sPTB, but the effect estimates were weaker for subsequent
sPTB.
2.5. Estrogen Metabolism Pathway
2.5.1. Estriol. Estriol is themajor form of circulating estrogen
during pregnancy [50] and measurements of estriol from
maternal saliva samples appear to correlate with maternal
serum levels [51, 52]. While some earlier studies demon-
strated that elevated (>2.1 ng/mL) salivary estriol was a better
marker for later sPTB in asymptomatic pregnant women
[53, 54], and the use of salivary estriol testing has potential
advantages (i.e., noninvasive nature and ease of collection and
approval by the Food and Drug Administration for use in
womenwith singleton gestations), onemajor limitation of the
use of saliva as a biomarker is confounding by factors such
as patient activity, posture, food consumption, and diurnal
variations in estriol levels [45, 55].
3. Use of Multiple Biochemical Markers
In addition to examining individual biochemical markers for
predicting preterm birth, there is a growing interest in devel-
oping assessment tools using multiple markers. Given the
heterogeneity of pathways leading to spontaneous preterm
birth, multiple markers increase sensitivity of prediction by
combining risk predictors that address diverse causes of
spontaneous pretermbirth [31]. In a nested case-control study
of 2,929 women with singleton gestations, Goldenberg et al.
[31] found that a positive level for at least one of three serum
biomarkers (serum alkaline phosphatase, maternal serum 𝛼-
fetoprotein, and granulocyte colony-stimulating factor) had
a collective sensitivity of 81% and specificity of 78% for the
prediction of spontaneous preterm birth at <32 weeks of
gestation and 60% sensitivity and 73% specificity for the
prediction of spontaneous preterm birth at <35 weeks of
gestation.
4. Racial Disparities, Gene-Environment,
Gene-Gene, and Epigenetics on Spontaneous
Preterm Birth
Although a number of individual or set of multiple biomark-
ers for sPTB have been explored and examined, high intra-
individual variability makes accurate prediction and subse-
quent prevention of preterm birth challenging. Advances in
molecular biology and improved sophistication in method-
ology and technology of genomics have allowed for many
investigators to turn their focus on the functional contribu-
tions of genetic variants to better understand preterm birth
overall, but more importantly, the racial disparity of preterm
birth [56–58]. According to 2010 data, preterm birth rate for
non-Hispanic African American women in the United States
was higher (17.1%) compared to non-Hispanic White women
(10.8%) [59] and such disparity has not been explained
fully by the differences in socioeconomic characteristics and
maternal behaviors shown in much earlier research [3]. A
growing body of literature provides emerging evidence for the
role of gene-gene interactions and gene-environment inter-
actions on preterm birth [56, 57, 60, 61] and the role of the
field of epigenetics in understanding pretermbirth [62]; given
limitations in study design and methodology, that is, many
were case-control studies where enrollment of cases and
specimen collection took place at the initiation of labor, no
study, thus far, has evaluated sPTB among asymptomatic
women and the racial-genetic relationships on the influences
of sPTB.
5. Conclusions
Although medical advances have improved the survival of
preterm infants and the treatment of short- and long-term
morbidities, little success has been attained in understanding
and preventing preterm birth. Great efforts have been spent
to characterize and define the utility of biologic fluids from
various sources in predicting sPTB. Not only does identifying
biochemical markers that are associated with sPTB allow
researchers to gain a better understanding on the underlying
mechanisms or pathways leading to preterm birth, but also,
this valuable tool can guide in designing the most effective
targeted intervention strategies aimed at women at risk for
preterm birth.
Many studies have evaluated the association between
individual or group biochemical marker(s) and sPTB among
asymptomatic women; to date, results of a number of bio-
chemical markers remain inconsistent. Understanding sPTB
is challenging due to its multifactorial etiologies and patho-
physiologic heterogeneity. Limitations from past studies on
biomarkers of sPTB including the identification of appropri-
ate study population (low risk versus high risk asymptomatic
women), gestational age at the time of specimen collection,
timing of collection relative to time of pregnancy outcome,
and the definition of study outcome (i.e., preterm birth phe-
notypes and gestational age at delivery) may lead to dis-
crepant findings. Furthermore, practicality and acceptability
and maternal and fetal risks also are of great concern. In
reviewing the literature, fetal fibronectin (>50 ng/mL, 24–26
weeks of gestation and beyond), thus far, is most effective in
predicting sPTB in asymptomatic women. Along with its
relatively high sensitivity, the required specimen collection
procedure is minimally invasive and poses little to no mater-
nal and fetal risks; the reliance of fetal fibronectin as a screen-
ing tool in clinical settings is justifiable in the management
and for providing timely interventions for women with pos-
itive results. Cervical length, a biophysical marker measured
by transvaginal ultrasound (not reviewed here), has been
promoted by the medical community as a valuable screening
tool for sPTB. While no evidence to date has suggested one
marker outperforming another, fetal fibronectin and cervical
length can be useful independently or jointly according to
woman’s a priori risk status for sPTB. Evidence in the current
literature also has indicated cervical IL-6 and 𝛼-fetoprotein,
in addition to fetal fibronectin, as potentially promising bio-
chemicalmarkers; however, little information on the sensitiv-
ity, specificity, and positive predictive value is known at this
time to determine the clinical usefulness of these markers.
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Additional research that improves understanding of the
mechanisms of preterm birth is important. In addition to the
development and validation of multiple biochemical markers
to be used independently or in conjunctionwith other clinical
and biophysical markers, demographic, and behavioral risk
factors, future work in this area should include further refine-
ment of study design and methodology in the evaluation of
gene-gene and gene-environment interaction studies and the
role of epigenetics in predicting sPTB across diverse popu-
lations.
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